Abridge announced new strategic partnerships with pharmaceutical company Eli Lilly and technology firm Nvidia on June 12, 2026. The collaborations aim to expand the artificial intelligence documentation company’s platform beyond its current provider-focused scribe tools to better connect with payers and life science entities. As part of the expansion, Abridge is working with Nvidia to develop a foundation model—a base model trained on large datasets for general-purpose applications—specifically designed for clinical conversations. Additionally, Eli Lilly has made a strategic investment in Abridge, though the specific financial terms of the deal were not disclosed. Abridge CEO Shiv Rao stated the investment is intended to support evidence-based care and research access at all moments of care.

Founded in 2018, Abridge provides an AI-powered scribe that records and summarizes medical encounters to reduce administrative burdens for clinicians. The company currently supports over 300 health systems, including major institutions such as Kaiser Permanente, Johns Hopkins Medicine, and Yale New Haven Health. Northwestern Medicine also plans to implement the technology across its health system. The AI tools currently include features for pre-visit summaries and query capabilities for clinical questions. The company is now seeking to integrate more deeply into claims resolution and clinical trial recruitment by leveraging medical record data to screen potential trial candidates. To facilitate these workflows, Abridge is collaborating with the American Health Information Management Association to align its coding capabilities with industry standards for fee-for-service and value-based care reimbursement.

The documentation market remains competitive, with electronic health record vendors such as Epic and Oracle Health also offering integrated AI features that could challenge pure-play documentation firms. To bolster its clinical decision support, Abridge has formed partnerships with several medical professional groups and journals, including the American Diabetes Association, the American Academy of Family Physicians, the journal Neurology, and the Journal of Clinical Oncology. These initiatives occur as health insurers express increasing concern that provider-side AI documentation could drive up overall healthcare costs. Industry analysts suggest that the growing adoption of AI by both providers and payers may lead to increased friction regarding reimbursement processes for patient care.

Abridge announced new strategic partnerships with pharmaceutical company Eli Lilly and technology firm Nvidia on June 12, 2026. The collaborations aim to expand the artificial intelligence documentation company’s platform beyond its current provider-focused scribe tools to better connect with payers and life science entities. As part of the expansion, Abridge is working with Nvidia to develop a foundation model—a base model trained on large datasets for general-purpose applications—specifically designed for clinical conversations. Additionally, Eli Lilly has made a strategic investment in Abridge, though the specific financial terms of the deal were not disclosed. Abridge CEO Shiv Rao stated the investment is intended to support evidence-based care and research access at all moments of care.

Founded in 2018, Abridge provides an AI-powered scribe that records and summarizes medical encounters to reduce administrative burdens for clinicians. The company currently supports over 300 health systems, including major institutions such as Kaiser Permanente, Johns Hopkins Medicine, and Yale New Haven Health. Northwestern Medicine also plans to implement the technology across its health system. The AI tools currently include features for pre-visit summaries and query capabilities for clinical questions. The company is now seeking to integrate more deeply into claims resolution and clinical trial recruitment by leveraging medical record data to screen potential trial candidates. To facilitate these workflows, Abridge is collaborating with the American Health Information Management Association to align its coding capabilities with industry standards for fee-for-service and value-based care reimbursement.

The documentation market remains competitive, with electronic health record vendors such as Epic and Oracle Health also offering integrated AI features that could challenge pure-play documentation firms. To bolster its clinical decision support, Abridge has formed partnerships with several medical professional groups and journals, including the American Diabetes Association, the American Academy of Family Physicians, the journal Neurology, and the Journal of Clinical Oncology. These initiatives occur as health insurers express increasing concern that provider-side AI documentation could drive up overall healthcare costs. Industry analysts suggest that the growing adoption of AI by both providers and payers may lead to increased friction regarding reimbursement processes for patient care.